Patents by Inventor Jørgen Schøller
Jørgen Schøller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150431Abstract: The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore, the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.Type: ApplicationFiled: November 21, 2023Publication date: May 9, 2024Inventors: Liselotte BRIX, Henrik PEDERSEN, Tina JAKOBSEN, Jørgen SCHØLLER, Jesper LOHSE, Katja BRUNSTEDT, Kivin JACOBSEN
-
Patent number: 10968269Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.Type: GrantFiled: December 30, 2008Date of Patent: April 6, 2021Assignee: Agilent Technologies, Inc.Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen
-
Publication number: 20210047383Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.Type: ApplicationFiled: June 23, 2020Publication date: February 18, 2021Inventors: Jørgen SCHØLLER, Liselotte BRIX, Henrik PEDERSEN
-
Publication number: 20200347114Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.Type: ApplicationFiled: June 13, 2019Publication date: November 5, 2020Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
-
Publication number: 20200347103Abstract: The present invention relates to MHC peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses thereof.Type: ApplicationFiled: February 13, 2020Publication date: November 5, 2020Inventors: Jørgen SCHØLLER, Liselotte BRIX, Henrik PEDERSEN, Tina JAKOBSEN
-
Patent number: 10611818Abstract: The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of.Type: GrantFiled: September 29, 2008Date of Patent: April 7, 2020Assignee: Agilent Technologies, Inc.Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen, Tina Jakobsen
-
Publication number: 20190314471Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.Type: ApplicationFiled: June 27, 2019Publication date: October 17, 2019Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
-
Patent number: 10369204Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.Type: GrantFiled: October 2, 2009Date of Patent: August 6, 2019Assignee: Dako Denmark A/SInventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
-
Publication number: 20190085048Abstract: The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore, the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.Type: ApplicationFiled: June 22, 2018Publication date: March 21, 2019Inventors: Liselotte Brix, Henrik Pedersen, Tina Jakobsen, Jørgen Schøller, Jesper Lohse, Katja Brunstedt, Kivin Jacobsen
-
Patent number: 10030065Abstract: The present invention relates to a soluble negative control MHC multimer comprising a nonsense peptide that binds the MHC protein efficiently, but that does not support binding of the resultant MHC-peptide complex to the desired T Cell Receptor. The nonsense peptide is designed to i) have a length enabling binding to the MHC allele in question, ii) have appropriate amino acids at relevant anchor positions which anchor the nonsense peptide to the peptide-binding groove of the MHC, iii) have amino acids outside the anchor positions that do not support binding to a T Cell Receptor, and iv) have an amino acid sequence that is different from the linear sequence of any naturally occurring peptide.Type: GrantFiled: December 22, 2009Date of Patent: July 24, 2018Assignee: Dako Denmark A/SInventors: Liselotte Brix, Henrik Pedersen, Tina Jakobsen, Jørgen Schøller, Jesper Lohse, Katja Brunstedt, Kivin Jacobsen
-
Publication number: 20150329617Abstract: Novel compounds carrying ligands capable of ligating to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as in various methods. In particular, novel MHC molecule constructs comprising one or more MHC molecules are disclosed. The affinity and avidity of the MHC molecules of the constructs are surprisingly high. The possibility of presenting to the target cells a plurality of MHC molecules makes the MHC molecule constructs an extremely powerful tool e.g. in the field of diagnosis. The invention relates in general to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC molecules, MHC molecule multimers, and MHC molecule constructs.Type: ApplicationFiled: March 13, 2002Publication date: November 19, 2015Applicants: DYNAL BIOTECH ASA, DAKO A/SInventors: Lars Winther, Lars Oestergaard Petersen, Soeren Buus, Joergen Schoeller, Erik Ruud, Oeystein Aamellem
-
Publication number: 20120264161Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.Type: ApplicationFiled: May 29, 2012Publication date: October 18, 2012Applicant: DAKO DENMARK A/SInventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
-
Publication number: 20120258126Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.Type: ApplicationFiled: October 2, 2009Publication date: October 11, 2012Applicant: DAKO DENMARK A/SInventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
-
Patent number: 8268964Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.Type: GrantFiled: November 16, 2009Date of Patent: September 18, 2012Assignee: Dako Denmark A/SInventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
-
Publication number: 20110318380Abstract: The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising cancer antigenic peptides and uses there of.Type: ApplicationFiled: October 1, 2009Publication date: December 29, 2011Applicant: DAKO DENMARK A/SInventors: Liselotte Brix, Jørgen Schøller, Henrik Pedersen
-
Publication number: 20100248257Abstract: The present invention relates to the fields of analysis, diagnostics, prognostics, standardization, characterization and enumeration of entities such as biological cells, as well as therapeutical applications. Accordingly, the present invention in preferred aspects is directed to methods for the detection and/or analysis and/or isolation and optionally further manipulation of entities, such as cells, particles, and supra-molecular structures.Type: ApplicationFiled: December 28, 2009Publication date: September 30, 2010Applicant: DAKO DENMARK A/SInventors: Kivin Jacobsen, Henrik Pedersen, Liselotte Brix, Jesper Lohse, Jørgen Schøller, Tina Jakobsen
-
Publication number: 20100226854Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.Type: ApplicationFiled: November 16, 2009Publication date: September 9, 2010Applicant: DAKO DENMARK A/SInventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix